Salute e Benessere

Grains of Truth 2024 - Global Insights on Healthy and Sustainable Food Systems

The report, based on insights from over 30,000 consumers across 31 markets, reveals that economic pressures, particularly rising food costs, are major obstacles. Price is the biggest hurdle, cited by 42% of respondents, while 35% are deterred by flavor. This is particularly true in North America and Europe, where affordability is a critical barrier. In the Asia-Pacific region, concerns about nutritional adequacy are prominent. The report, based on insights from over 30,000 consumers across 31...
PR Newswire
30/01/2025

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang…

GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestonesClosing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meetingFinancing would extend cash runway beyond the end of 2027, assuming drawdown of all instalmentsProceeds to further strengthen the development...
Nasdaq GlobeNewswire
30/01/2025

Electrolux Group Year-end report Q4 2024

Highlights of the fourth quarter of 2024 Highlights of the fourth quarter of 2024 President and CEOYannick Fierling'scomment After having spent 3 months getting to know Electrolux Group and its stakeholders, I assumed the position as CEO onJanuary 1, 2025. In the fourth quarter, we continued to make good progress on our cost reduction initiatives, and the Group's attractive product offering contributed to an organic growth of 11.5%. Operating margin excluding non-recurring...
PR Newswire
30/01/2025

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded…

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.31Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIODupixent sales up 16.0% to €3.5 billionVaccines sales up 10.8% to €2.2 billion, driven by Beyfortus sales in EuropeBusiness EPS of €1.31, -11.0% at CER and -14.9% reported;...
Nasdaq GlobeNewswire
30/01/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results…

Group salesgrew by 7% 1at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19,Group salesincreased by 9%. COVID-19 will not adversely impact our results from 2025 onwards.Thefourth quarterwas the third consecutive quarter of 9% sales growth, highlighting the very positive momentum. Pharmaceuticals Division salesrose by 8% (excluding COVID-19 medicine: 9%) on growing demand for newer medicines; top...
Nasdaq GlobeNewswire
30/01/2025

Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the…

Key Takeaways from the Endometriosis Pipeline Report Key Takeaways from the Endometriosis Pipeline Report Request a sample and discover the recent advances in endometriosis treatment drugs @Endometriosis Pipeline Report The endometriosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometriosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an...
PR Newswire
29/01/2025

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,526,245,442 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
29/01/2025

Nanobiotix to Participate in Multiple Investor Conferences in February and March…

PARIS and CAMBRIDGE, Mass., Jan.29, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: Guggenheim SMID Cap Biotech Conference Date: Thursday, February 6, 2025 Time: 1pm ET / 7pm...
Nasdaq GlobeNewswire
29/01/2025

GENFIT Announces 2025 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025. 2025 Financial Calendar February 27, 2025Publication of revenue and cash position at December 31, 2024April 24, 2025 Publication of Full...
Nasdaq GlobeNewswire
29/01/2025

EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE…

"This approval represents a significant advancement, offering patients the opportunity to receive BLINCYTO earlier in their treatment pathway, with the potential to improve outcomes," said Jean-Charles Soria, senior vice president of Global Oncology Development at Amgen. "The E1910 data that served as the basis of this approval adds to the growing body of evidence of the meaningful survival impact of BLINCYTO." "This approval represents a significant advancement…
PR Newswire
29/01/2025

Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses…

"Successfully completing the HRIPT testing and achieving a sales milestone of 5,000 units per day on average underscores our strong commitment to providing the highest quality products that are in demand by the market," commented Roni Kamhi, CEO of BI Sky Global. "This positions us very well for further expansion in sales and marketing as we capitalize on our success and bring the highest quality products to market." "Successfully completing the HRIPT testing and…
PR Newswire
29/01/2025

Inventiva announces the publication of the results from the…

As previously reported 1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy ( 1 H-MRS) following 24 weeks of treatment in patients with MASLD and T2DA significantly higher proportion of patients achieved a greater than 30% liver triglyceride reduction as well as MASLD resolution with lanifibranor compared to placeboLanifibranor treatment significantly...
Nasdaq GlobeNewswire
29/01/2025

AB Science today provides an update on its masitinib platform

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORMParis, January 29, 2025, 7pm CETAB Science SA(Euronext - FR0010557264 - AB) today provides an update on its masitinib platform. The webcast presentation is available on the company's website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ Highlights of the presentation are the following:Amyotrophic lateral sclerosis New confirmatory study AB23005...
Nasdaq GlobeNewswire
29/01/2025

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to…

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision ImmunotherapyNantes and Paris - France, January 29, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Scienta Lab, a leader in Artificial Intelligence (AI)-driven precision immunology, announce a strategic collaboration to harness Scienta Lab's advanced AI platform for modeling inflammatory diseases and identifying predictive biomarkers...
Nasdaq GlobeNewswire
29/01/2025

New Survey from Clue Identifies Key Solutions for Increasing Life-Saving…

Survey Shows that Healthcare Provider Support and Self-Administered Cervical Cancer Screening Options Can Ease Testing Anxiety and Increase Willingness to Participate in Screenings Clue , the most trusted, data-driven period and reproductive health tracking app, released aClue community insight surveyrevealing the top barriers women and people with cycles face when considering cervical screenings. After surveying over 7,800 of its members from around the world, Clue found that while...
Nasdaq GlobeNewswire
29/01/2025

Poultry Medicine/Pharmaceuticals Market to Hit USD 6.68 Billion by 2029 with…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=112094232 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=112094232 Browse in-depth TOC on "Poultry Medicine/Pharmaceuticals Market" 500 - Tables 56 - Figures 424 - Pages Based on animal type,the chickens registered the highest share in cold plasma market, people all over the world eat a lot of chicken and eggs, which makes them affordable sources of protein...
PR Newswire
29/01/2025

Image Analysis Group Announces Release of DYNAMIKA V.7, their Award-Winning…

DYNAMIKA was recently named an Award Category Winner for Innovation in the 2024 Pharmaceutical Technology Excellence Awards, recognizing the platform's proprietary technology and its potential for driving change in the pharmaceutical industry. DYNAMIKA was recently named an Award Category Winner for Innovation in the 2024 Pharmaceutical Technology Excellence Awards , recognizing the platform's proprietary technology and its potential for driving change in the pharmaceutical industry...
PR Newswire
29/01/2025

Stem Cell Factor (SCF) Market: Forecast to Grow at a 11.4% CAGR, Driven by…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-10V18247/Global_Stem_Cell_Factor_SCF_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-10V18247/Global_Stem_Cell_Factor_SCF_Market Major Factors Driving the Growth of Stem Cell Factor Market: The Stem Cell Factor (SCF) Market is poised for substantial growth, driven by the increasing demand for SCF in therapeutic and research applications across diverse healthcare...
PR Newswire
29/01/2025

TIME TO RECONNECT: THIS VALENTINE'S DAY, LEGO® BOTANICALS SETS OFF ON GLOBAL…

When people replace real-world interaction with screen time, it has been foundv that feelings of disconnection increase and well-being declines. That's why the LEGO Group is on a mission to help real-world relationships bloom this Valentine's Day and beyond. When people replace real-world interaction with screen time, it has been found vthat feelings of disconnection increase and well-being declines. That's why the LEGO Group is on a mission to help real-world relationships bloom this...
PR Newswire
29/01/2025

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of…

LONDON and NEW YORK, Jan.29, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, today announces a clinical update and its interim results for the six months ended 30 September 2024.Clinical Updates:OK-101 ...
Nasdaq GlobeNewswire
29/01/2025

LEE KUM KEE CELEBRATES ASIAN CUISINE AND CULTURE IN GLOBAL "FLAVOURS THAT BIND"…

"Founded 137 years ago, Lee Kum Kee remains true to its mission of promoting Chinese culinary culture worldwide while advancing the reach and influence of Asian cuisine to meet the growing global appetite for new and exciting flavours. As Asian food, music, and cinema increasingly resonate with people around the world, Lee Kum Kee is seizing this moment to further champion Asian culinary traditions and culture," Jet Jing, Chief Executive Officer of Lee Kum Kee Sauce, explains…
PR Newswire
29/01/2025

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial…

2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO ®- exceeding $1.6 billion in revenues, surpassing 2024 outlook;AJOVY ®- global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023;UZEDY ®revenues of $117 million in 2024 surpassing $100M outlook;Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets,...
Nasdaq GlobeNewswire
29/01/2025

Asia Book of Records Honors Cipla (Emerging Markets & Europe business unit) for…

This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month. This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month. Commenting on this recognition,Swapn Malpani, CEO – Cipla EMEUsaid, "COPD is recognized as a progressive lung condition and ranks as the fourth leading cause of...
PR Newswire
29/01/2025

Piramal Pharma Limited Announces Results for Q3 and 9M FY25

Key Highlights for Q3FY25/9MFY25 Key Highlights for Q3FY25/9MFY25 Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, " FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work. Our CHG business registered an early-teen revenue growth during the...
PR Newswire
29/01/2025
Altri  Comunicati